Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2023 | Genitourinary cancer updates at ASCO 2023

Toni Choueiri • 22 May 2023
ASCO 2023
Genitourinary Cancer Kidney Cancer Prostate Cancer Antibodies Pembrolizumab
CLEAR

Toni Choueiri, MD, Dana-Farber Cancer Institute, Boston, MA, shares his anticipations ahead of at the American Society of Clinical Oncology (ASCO) 2023 including a presentation on the latest results from the Phase III CLEAR (NCT02811861) study that established pembrolizumab as the first-line standard of care in renal-cell carcinoma (RCC). This interview took place at ASCO 2023 Annual Congress in Chicago, IL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Toni Choueiri

4:15
CONTACT-303: primary PFS analysis of atezolizumab and cabozantinib in ccRCC
Toni Choueiri • 22 May 2023
1:17
Optimal therapy sequencing in kidney cancer
Toni Choueiri • 22 May 2023
1:05
Cohort 1 LITESPARK-003: belzutifan + cabozantinib 1L treatment for advanced RCC
Toni Choueiri • 12 Sep 2022
1:49
COSMIC-313: cabozantinib with nivolumab and ipilimumab in untreated aRCC
Toni Choueiri • 12 Sep 2022

Related Videos

4:05
Evaluating triplet therapy in metastatic hormone sensitive prostate cancer
Nick James • 24 Apr 2024
10:42
Management of prostate cancer from the patient perspective
David Matheson • 11 Apr 2024
2:26
Prognostic factors of renal cell cancer in elderly patients
Teemu Murtola • 9 Apr 2024
2:44
The effect of hypoxia on lipid metabolism and prostate cancer tumor growth
Teemu Murtola • 9 Apr 2024
The content of VJOncology is intended for healthcare professionals